Reducing CD73 expression by IL1β-programmed Th17 cells improves immunotherapeutic control of tumors

Cancer Research

Volumn 74, Issue 21, 2014, Pages 6048-6059

  Chatterjee, Shilpak ^a   Thyagarajan, Krishnamurthy ^a   Kesarwani, Pravin ^a   Song, Jin H ^a   Soloshchenko, Myroslawa ^a   Fu, Jianing ^a   Bailey, Stefanie R ^a   Vasu, Chenthamarkshan ^a   Kraft, Andrew S ^a   Paulos, Chrystal M ^a   Yu, Xue Zhong ^a   Mehrotra, Shikhar ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE TRIPHOSPHATASE; CD39 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH RECEPTOR; PYRUVIC ACID; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; APYRASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IL1B PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; NT5E PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; EX VIVO STUDY; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH0 CELL; TH1 CELL; TH17 CELL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ANIMALS; ANTIGENS, CD; APYRASE; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GPI-LINKED PROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-1BETA; MICE; NEOPLASMS; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84909606726     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1450     Document Type: Article

References (50)

1. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med 2012;4:127ps8.
2. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res 2011;71:6567-71.
3. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: costimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol 2009;157:9-19.
4. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 2004;101: 1969-74.
5. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362-73.
6. Lu Y, Hong S, Li H, Park J, Hong B, Wang L, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012;122: 4160-71.
7. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Upregulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116.
8. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
9. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
10. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011;35:972-85.
11. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med 2011;3:104ra00.
12. YuY, Iclozan C,Yamazaki T,Yang X,Anasetti C,Dong C, et al.Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. Blood 2009;114:1026-8.
13. Tartar DM, VanMorlan AM, Wan X, Guloglu FB, Jain R, Haymaker CL, et al. FoxP3+RORgammat +T helper intermediates display suppressive function against autoimmune diabetes. J Immunol 2010; 184:3377-85.
14. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice. J Immunol 2012; 189:1627-38.
15. Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014;134:1285-94.
16. Ferrick DA, Neilson A, Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008; 13:268-74.
17. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS ONE 2008;3:e2599.
18. Ghiringhelli F, Bruchard M, Chalmin F, Rebe C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012;2012:473712.
19. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012;36:362-73.
20. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic T(H)17 cells in the absence of TGFbeta signalling. Nature 2010;467:967-71.
21. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012;188:5438-47.
22. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314-24.
23. Mus AM, Cornelissen F, Asmawidjaja PS, van Hamburg JP, Boon L, Hendriks RW, et al. Interleukin-23 promotes Th17 differentiation by inhibiting T-bet and FoxP3 and is required for elevation of interleukin-22, but not interleukin-21, in autoimmune experimental arthritis. Arthritis Rheum 2010;62:1043-50.
24. Duhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E. Cutting edge: the pathogenicity of IFN-gamma-producing Th17 cells is independent of T-bet. J Immunol 2013;190:4478-82.
25. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011;32:395-401.
26. Starbeck-Miller GR, Xue HH, Harty JT. IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining highaffinity IL-2 signaling in vivo. J Exp Med 2014;211:105-20.
27. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013;38:633-43.
28. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, et al. Mitochondria are required for antigen-specific T-cell activation through reactive oxygen species signaling. Immunity 2013;38:225-36.
29. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T-cell effector function by aerobic glycolysis. Cell 2013;153:1239-51.
30. Cham CM, Gajewski TF. Glucose availability regulates IFN-gamma production and p70S6 kinase activation in CD8+ effector T cells. J Immunol 2005;174:4670-7.
31. Badovinac VP, Corbin GA, Harty JT. Cutting edge: OFF cycling of TNF production by antigen-specific CD8+ T cells is antigen independent. J Immunol 2000;165:5387-91.
32. Corbin GA, Harty JT. T cells undergo rapid ON/OFF but not ON/OFF/ ON cycling of cytokine production in response to antigen. J Immunol 2005;174:718-26.
33. Karlsson S. Is TGF-beta a stemness regulator? Blood 2009;113:1208.
34. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 2013;123:4479-88.
35. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
36. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
37. Lu Y, Hong B, Li H, Zheng Y, Zhang M,WangS, et al. Tumor-specific IL-9-producing CD8+Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci U S A 2014;111:2265-70.
38. Regateiro FS, Howie D, Nolan KF, Agorogiannis EI, Greaves DR, Cobbold SP, et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol 2011;41: 2955-65.
39. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008;455:808-12.
40. Hu W, Troutman TD, Edukulla R, Pasare C. Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. Immunity 2011;35:1010-22.
41. Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res 2010;70:6407-11.
42. Allard B,PommeyS, Smyth MJ, Stagg J. TargetingCD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013;19:5626-35.
43. Zhang B. Opportunities and challenges for anti-CD73 cancer therapy. Immunotherapy 2012;4:861-5.
44. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012;72:2190-6.
45. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65.
46. Ben-Sasson SZ, Hogg A, Hu-Li J, Wingfield P, Chen X, Crank M, et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013; 210:491-502.
47. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S, Ratner M, Shapira I, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009; 106:7119-24.
48. Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T-cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 2011;1812:246-51.
49. Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-50-nucleotidase (CD73) regulation by hypoxiainducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002;110:993-1002.
50. Lu XX, ChenYT, Feng B,MaoXB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma. World J Gastroenterol 2013;19:1912-8.